ACOD1 and neoplasm: Compared with other groups, the combination of the low-dose anti-PD1 antibody with ACOD1-/- MSLN-CAR-iMACs had the most superior tumor suppression effect (Fig. 7g), and markedly lengthened the survival time (Fig. 7h).